Рациональная фармакотерапия в кардиологии (Jul 2024)

Severe myocardial hypertrophy and fibrosis in a patient with acromegaly: is the prevention of sudden cardiac death needed?

  • A. A. Almaskhanova,
  • K. V. Melkozerov,
  • E. G. Przhiyalkovskaya,
  • N. V. Tarbaeva,
  • R. S. Kosharnaia,
  • I. S. Gomova,
  • P. A. Alferova,
  • L. Ya. Rozhinskaya,
  • V. Y. Kalashnikov,
  • Zh. E. Belaya,
  • G. A. Melnichenko,
  • N. G. Mokrysheva

DOI
https://doi.org/10.20996/1819-6446-2024-3063
Journal volume & issue
Vol. 20, no. 3
pp. 349 – 356

Abstract

Read online

The most common causes of death in acromegaly are cardiovascular diseases (about 60%). Heart arrhythmias and conduction disorders lead to sudden cardiac death (SCD). In this article, we described a clinical case about preventing SCD in a patient with acromegaly. We identified in this patient predictors of SCD: severe left ventricular hypertrophy, the signs of myocardial fibrosis, decreased systolic function of the left ventricular myocardium, ventricular rhythm disturbances, and heart failure. Patients with acromegaly have higher risk of heart arrhythmias due to development acromegalic cardiomyopathy with includes: left ventricular hypertrophy, diastolic and systolic dysfunction, myocardial fibrosis and electrical disturbances of the myocardium. The main limitation is the lack of special clinical recommendations for the management of this group of patients. Current recommendations based on a standard algorithm and do not consider specificity of acromegalic cardiomyopathy.

Keywords